Discussing the effect of canagliflozin in patients with diabetes and chronic kidney disease with Meg Jardine, MBBS, PhD.
Results of a new study from the American Diabetes Association (ADA) 80th Scientific Sessions suggests use of canagliflozin not only reduces incidence of first hospitalizations for heart failure events, but recurrent events as well.
A post-hoc analysis of the CREDENCE trial, results of the study indicated canagliflozin reduced the rate of total hospitalization for heart failure events by 36% in type 2 diabetics with chronic kidney disease.
“For clinicians, I think the main message is: keep your patients on the medication, particularly if they are at risk of heart failure,” said lead investigator Meg Jardine, MBBS, PhD, in a recent interview with HCPLive. “If they’ve already had a heart failure episode, it is more important to keep them on canagliflozin because it will be reducing their rate of subsequent events.”
Using data from the CREDENCE trial, investigators identified a total of 326 hospitalizations for heart failure events among 230 patients. Of these 320, 166 had 1 event, , 43 had 2 events, 15 had 3 events, and 6 had 4 events or more. Based on this, 42% of those who experienced at least 1 event suffered from a recurrent event during the trial.
Upon analysis, investigators found canagliflozin use was associated with a 39% (HR, 0.61; 95% CI, 0.47-0.80; P <0.001; NNT, 46; 95% CI 29-124) reduction in risk for first hospitalization for heart failure event and a 36% reduction in total hospitalizations for heart failure (incidence rate ratio, 0.64; 95% CI, 0.56-0.73; P <.001).
To learn more about the effects of canagliflozin on total and first heart failure events in patients with type 2 diabetes and chronic kidney disease, HCPLive invited Jardine to take part in an ADA 2020 House Call.
This study, “Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease,” was presented at ADA 2020.